| Título : |
Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study |
| Tipo de documento : |
documento electrónico |
| Autores : |
Kenny Mauricio Gálvez Cárdenas, |
| Fecha de publicación : |
2022 |
| Títulos uniformes : |
Clinical Lymphoma, Myeloma & Leukemia
|
| Idioma : |
Inglés (eng) |
| Palabras clave : |
Multiple myeloma Colombia Diagnosis Therapy autologous transplantation disease registry real-world |
| Resumen : |
Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America is available, and access to novel agents for a substantial portion of the population is limited by their high costs. 1 . In this multicenter cohort study, data on 890 Colombian MM patients are reported with a median follow-up of 18 months (IQR: 7-42 months). Patients were classified by age group (≤ or > 65 years). Median age at diagnosis was 67 years (IQR: 59-75 years) and 47.1% of patients were women. 709 patients (79.6%) received Bortezomib-based schemes as part of the first line, with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) being the most frequently used (301 patients; 33.8%). Only two hundred and fifty-two patients (28.3%) were consolidated with Autologous Stem Cell Transplantation (ASCT) in first-line therapy. ASCT consolidation and age were the main independent factors influencing outcomes; in the non-ASCT cohort, 5-year overall survival was 48.7% (CI 41.8-55.2) compared to 80.7% (CI 73-86.4) in ASCT patients. This data depicts the reality of MM in Colombia, which likely reflects other Latin American countries, where access barriers to diagnosis and treatment are echoed in advanced stage diagnosis and a low rate of transplants. These seem to negatively impact survival despite the availability of most novel drugs approved in most of the world for this disease. Thus, emphasizing the paradox that prevails in most of the region: availability without equitable access. |
| Mención de responsabilidad : |
Virginia Abello, William Armando Mantilla, Henry Idrobo, Claudia Lucia Sossa, Luis Antonio Salazar, Angela Pena, Juan Manuel Herrera, Paola Guerrero, Daniel Espinosa, Guillermo Enrique Quintero-Vega, Isabel Munevar, Kenny Galvez, Alicia Henao, Rigoberto Gómez, Jose Domingo Saavedra, Lina María Gaviria, Mónica Osuna y María Victoria Mateos |
| Referencia : |
Clin Lymphoma Myeloma Leuk. 2021 Dec 13;S2152-2650(21)02478-2. |
| DOI (Digital Object Identifier) : |
10.1016/j.clml.2021.12.009 |
| PMID : |
35042679 |
| En línea : |
https://linkinghub.elsevier.com/retrieve/pii/S2152265021024782 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5841 |
Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2022. Obra : Clinical Lymphoma, Myeloma & LeukemiaIdioma : Inglés ( eng) | Palabras clave : |
Multiple myeloma Colombia Diagnosis Therapy autologous transplantation disease registry real-world |
| Resumen : |
Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America is available, and access to novel agents for a substantial portion of the population is limited by their high costs. 1 . In this multicenter cohort study, data on 890 Colombian MM patients are reported with a median follow-up of 18 months (IQR: 7-42 months). Patients were classified by age group (≤ or > 65 years). Median age at diagnosis was 67 years (IQR: 59-75 years) and 47.1% of patients were women. 709 patients (79.6%) received Bortezomib-based schemes as part of the first line, with Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) being the most frequently used (301 patients; 33.8%). Only two hundred and fifty-two patients (28.3%) were consolidated with Autologous Stem Cell Transplantation (ASCT) in first-line therapy. ASCT consolidation and age were the main independent factors influencing outcomes; in the non-ASCT cohort, 5-year overall survival was 48.7% (CI 41.8-55.2) compared to 80.7% (CI 73-86.4) in ASCT patients. This data depicts the reality of MM in Colombia, which likely reflects other Latin American countries, where access barriers to diagnosis and treatment are echoed in advanced stage diagnosis and a low rate of transplants. These seem to negatively impact survival despite the availability of most novel drugs approved in most of the world for this disease. Thus, emphasizing the paradox that prevails in most of the region: availability without equitable access. |
| Mención de responsabilidad : |
Virginia Abello, William Armando Mantilla, Henry Idrobo, Claudia Lucia Sossa, Luis Antonio Salazar, Angela Pena, Juan Manuel Herrera, Paola Guerrero, Daniel Espinosa, Guillermo Enrique Quintero-Vega, Isabel Munevar, Kenny Galvez, Alicia Henao, Rigoberto Gómez, Jose Domingo Saavedra, Lina María Gaviria, Mónica Osuna y María Victoria Mateos |
| Referencia : |
Clin Lymphoma Myeloma Leuk. 2021 Dec 13;S2152-2650(21)02478-2. |
| DOI (Digital Object Identifier) : |
10.1016/j.clml.2021.12.009 |
| PMID : |
35042679 |
| En línea : |
https://linkinghub.elsevier.com/retrieve/pii/S2152265021024782 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5841 |
|  |
Inicio
Clasificado(s) por (Año de edición descendente) Refinar búsquedaReal-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study / Kenny Mauricio Gálvez Cárdenas
